With the year nearing its midpoint, it is evident that AI stocks, especially those of the generative type, have been the standout trend. However, there is still opportunity to invest in them.
3 top AI stocks to purchase in June Read More »
Zepbound is a new weight-loss drug from Eli Lilly. According to Goldman Sachs, the anti-obesity drug market is expected to reach $130 billion by 2030, with new products like Zepbound contributing to this growth.
Zepbound, Eli Lilly’s latest weight-loss medication, is projected to contribute to the growing anti-obesity drug market, which is forecasted to reach $130 billion by 2030 according to Goldman Sachs. Emerging products like Zepbound are expected to drive this market expansion.
The weight-loss drug Zepbound, developed by Eli Lilly, is a new addition to the market. Goldman Sachs predicts that the anti-obesity drug market will reach a value of $130 billion by 2030, with new products like Zepbound contributing to this growth.
The transcript of Lam Research Corporation (LRCX) at the Goldman Sachs Global Semiconductor Conference.
The transcript of Lam Research Corporation’s presentation at the Goldman Sachs Global Semiconductor Conference.
Click here to view the full story on The Fly’s website. Thefly.com offers up-to-date financial news and is considered a top source for market intelligence. Their live news feed provides continuous updates for individuals.
AstraZeneca was given a positive outlook by Goldman Sachs due to specific reasons. Read More »
Click here to read the rest of the story. Thefly.com offers up-to-date financial news and is recognized for its market intelligence. Their live news feed provides ongoing updates for individuals.
AstraZeneca has been given a positive outlook by Goldman Sachs for certain reasons. Read More »
Paraphrase: Western Digital Corporation recently participated in the Goldman Sachs Global Semiconductor Conference.
Read More: https://seekingalpha.com/news/4111238-goldman-sachs-raises-over-20b-to-invest-in-private-credit?utm_source=feed_news_all&utm_medium=referral&feed_item_type=news
Stay updated with the latests analysis and insights fromm etfsector.com
